Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epoetin alfa, darbepoetin) and number of weeks of ES...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Duong, Vu H., Baer, Maria R., Hendrick, Franklin, Weiss, Sheila R., Sato, Masayo, Zeidan, Amer M., Gore, Steven D., Davidoff, Amy J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4441842/
https://ncbi.nlm.nih.gov/pubmed/25869077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.03.013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky